<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402532</url>
  </required_header>
  <id_info>
    <org_study_id>Ever-Lung-DE01/RAD-LungDE01</org_study_id>
    <nct_id>NCT00402532</nct_id>
  </id_info>
  <brief_title>Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation</brief_title>
  <official_title>Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Everolimus is effective in the treatment
      and prevention of chronic graft dysfunction and chronic graft rejection after lung
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of bronchiolitis obliterans syndrome and mortality and need for change of immunosuppressive medication within 2 years from transplantation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Nephrotoxicity within 2 years of transplantation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of opportunistic infections within 2 years of transplantation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolatmofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Initial dosage 2 x 0.75 mg/d</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolatmofetil</intervention_name>
    <description>Initial dosage 2 x 500 mg/d intravenous</description>
    <arm_group_label>Mycophenolatmofetil</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient of Single or Bilateral Lung Transplantation

          -  Informed consent

          -  Recipients who are able to receive Everolimus at week 3 after Lung Transplantation

          -  women of childbearing potential must have a negative pregnancy test within 48 hours of
             enrolment

          -  women of childbearing potential must use appropriate contraceptive method at
             enrolment, during the study and up to 8 weeks after the end of the study

          -  donor must not have relevant pulmonary diseases

          -  donor must have oxygen partial pressure higher than 300 mmHg at FiO 1.0 and positive
             end-expiratory pressure of 5 cm H2O.

        Exclusion Criteria:

          -  systemic infection of the donor

          -  donor: signs or symptoms of aspiration

          -  donor: severe pulmonary injury or contusion

          -  donor: malignant neoplasm of the lung

          -  donor: HIV positive

          -  recipients who receive immunosuppressive agents not used in this protocol

          -  recipients who participated within 30 days before study start or are currently
             participating in another investigational drug trial

          -  HIV positive recipient

          -  systemic infection of the recipient

          -  recipients of combined/ multiple transplantations

          -  pregnancy of the recipient

          -  recipients with signs/ Symptoms of impaired wound healing of the pulmonary anastomoses

          -  recipients who are still on artificial respiration or who are not able to swallow
             tablets at week 3 after transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Strueber, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School, Division of Thoracic and Cardiovascular Surgery</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Martin Strueber</investigator_full_name>
    <investigator_title>Martin Strueber, MD</investigator_title>
  </responsible_party>
  <keyword>Lung Transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Mortality</keyword>
  <keyword>Graft rejection</keyword>
  <keyword>Bronchiolitis obliterans</keyword>
  <keyword>Opportunistic infections</keyword>
  <keyword>Nephrotoxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

